Search Results - "Álvarez Rivas, Miguel Angel"

Clinical Characteristics, Treatment Approach and Long-Term Outcomes of 678 Patients with Symptomatic Waldenstrom's Macroglobulinemia: Comprehensive Insights from a Spanish Registry of IgM Gammapathies by Askari, Elham, Moreno, David F., Escalante, Fernando, Domingo-González, Amalia, Heredia, Angela, Bermúdez, Arancha, Canales, Miguel, Herraiz, Mario Arnao, Alcala Peña, Maria Magdalena, Saus Carreres, Ana, Ríos Rull, Pablo, Casanova, María, Gironella, Mercedes, Ribas Garcia, Paz, De La Rubia, Javier, Navarro, Belén, Blanchard, María-Jesús, Motlló, Cristina, García Sánchez, Ricarda, Taboada Alameda, Francisco, Garcia, Antonio, Abella, Eugenio, Alvarez Rivas, Miguel Angel, Bargay, Joan, Sabater, Laura Abril, Lopez Picado, Amanda, Fernández de Larrea, Carlos, Garcia-Sanz, Ramon

“…Introduction The pathogenesis of Waldenstrom's macroglobulinemia (WM) involves the clonal expansion of lymphoplasmacytic B cells in bone marrow, producing…”
Get full text

Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance by Mateos, María-Victoria, Martínez-López, Joaquin, Rodriguez Otero, Paula, González-Calle, Verónica, Gonzalez, Marta Sonia, Oriol, Albert, Gutiérrez, Norma C, Ríos-Tamayo, Rafael, Rosiñol, Laura, Alvarez Rivas, Miguel Angel, Bargay, Joan, Gonzalez-Rodriguez, Ana Pilar, Alegre, Adrián, Escalante, Fernando, Iñigo Rodríguez, María Belén, De La Rubia, Javier, Teruel, Ana Isabel, de Arriba, Felipe, Palomera, Luis, Hernández, Miguel T, Lopez Jiménez, Javier, Reinoso-Segura, Marta, García Mateo, Aránzazu, Ocio, Enrique M, Paiva, Bruno, Puig, Noemi, Cedena, M Teresa, Bladé, Joan, Lahuerta, Juan Jose, San-Miguel, Jesus F

“…Early treatment of high-risk smoldering myeloma has been shown to delay progression to multiple myeloma (MM). We conducted this trial with curative intention…”
Get full text

Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial by Puig, Noemi, Agullo, Cristina, Contreras, Teresa, Paiva, Bruno, Cedena Romero, Maria Teresa, Pérez, José Juan, Aires, Irene, Martinez-Lopez, Joaquin, Rodriguez Otero, Paula, Gonzalez-Calle, Veronica, Gonzalez Perez, Marta Sonia, Gutierrez, Norma C., Rocafiguera, Albert Oriol, Ríos, Rafael, Rosiñol, Laura, Alvarez Rivas, Miguel Angel, Calasanz, Maria Jose, Joan, Bargay, Garcia-Sanz, Ramon, Gonzalez, Ana Pilar, Alegre, Adrián, Escalante, Fernando, Martínez, Rafael, De La Rubia, Javier, Teruel, Ana Isabel, De Arriba, Felipe, Palomera, Luis, Castro, Sergio, Hernández Garcia, Miguel Teodoro, López, Javier, García Mateo, Aránzazu, Ocio, Enrique M, Bladé, Joan, Lahuerta Palacios, Juan Jose, San Miguel, Jesús, Mateos, Maria Victoria

“…Background: GEM-CESAR trial is a potentially curative strategy for high-risk smoldering multiple myeloma (HRsMM) patients (pts) in which the primary endpoint…”
Get full text

Cold agglutinin disease of IgA class as early manifestation of multiple myeloma and resolution after treatment with new anti-myeloma drugs by Chic Acevedo, Carolina, García Torres, Estefanía, Álvarez Rivas, Miguel Ángel

Get more information

Cold agglutinin disease of IgA class as early manifestation of multiple myeloma and resolution after treatment with new anti-myeloma drugs by Chic Acevedo, Carolina, García Torres, Estefanía, Álvarez Rivas, Miguel Ángel

Get full text